Cita APA

Previtali, S., Gidaro, T., Diaz-Manera, J., Zambon, A., Carnesecchi, S., Roux-Lombard, P., . . . Muntoni, F. (2020). Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.

Citación estilo Chicago

Previtali, SC, et al. Rimeporide As a First- In-class NHE-1 Inhibitor: Results of a Phase Ib Trial in Young Patients With Duchenne Muscular Dystrophy. 2020.

Cita MLA

Previtali, SC, et al. Rimeporide As a First- In-class NHE-1 Inhibitor: Results of a Phase Ib Trial in Young Patients With Duchenne Muscular Dystrophy. 2020.